BCX-34 topical small molecule inhibitor of purine nucleoside phosphorylase data

BCRX (Birmingham, Ala.) announced results of an open-label Phase II trial, showing remissions in 7 of the 24 patients with Stage I/IIA disease.

Two additional patients were clinically clear of disease and 9 had partial remissions. The remaining 6 patients did not improve or got worse. ...